logo

Palatin Technologies Inc. (PTN)



Trade PTN now with
  Date
  Headline
8/5/2020 7:32:41 AM Palatin Technologie Completes Enrollment Of Phase 2 Study With PL9643 For Dry Eye Disease
7/27/2020 7:01:48 AM Palatin Technologies Mutually Terminates License Agreement With AMAG Pharmaceuticals For Vyleesi
7/8/2020 7:31:55 AM Palatin Technologies Announces Reinitiation Of Enrollment Of Phase 2 Study With PL9643
6/29/2020 7:33:04 AM Palatin Technologies Announces Adjournment Of Annual Meeting Of Stockholders Until July 23, 2020
6/23/2020 7:32:36 AM Palatin Technologies Says Developing PL8177 As A Treatment For Patients With COVID-19
5/12/2020 7:33:13 AM Palatin Technologies Q3 Net Loss $5.4 Mln Or $0.02/shr Vs. Net Loss Of $5.7 Mln Or $0.03/shr Prior Year
2/19/2020 7:31:14 AM Palatin Technologies Announces First Patient Enrolled In Dry Eye Disease Phase 2 Clinical Trial With PL9643
2/11/2020 7:33:36 AM Palatin Technologies Q2 Net Loss $5.2 Mln Or $0.02/Shr Vs Net Loss $5.0 Mln Or $0.02/Shr Last Year
1/21/2020 7:32:14 AM Palatin Technologies Sees Dry Eye Disease Phase 2 Study To Commence Q1 2020 With Data In Q4 2020